The possibility is therefore prospected that specific Fibromodulin-derived peptides may be exploited as tumour vaccines for the treatment of CLL-B, unless it would turn out that such peptides may evoke collateral cartilage-directed inflammatory reactions. This evidence concerns the gene FMOD and neoplasm.